cardiovascular disease

Heart and blood-vessel disease: drugs and devices that treat or prevent it.

Theme · 16 companies · 3 report it as a revenue line

Show
8-K events
Match any selected event
8-K event types
More events

Only filters 8-Ks. Other selected forms stay visible.

Role
  • ABT Abbott Laboratories

    Sells it“9M FX-adjusted growth included Electrophysiology +13.8%, Rhythm Management +10.6%, Heart Failure +8.9%, Vascular +5.2%, Structural Heart +2.6%, Neuromodulation +1.3% and Diabetes Care +7.7%.”

    Latest 8-KExecutive pay ·

    Change-in-control agreements extended through Dec. 31, 2028 for named executives except CEO Robert B. Ford, whose agreement expires Dec. 31, 2026.

  • ADRX ADARx Pharmaceuticals, Inc.

    In development“Our Factor XI (FXI) program, ADX-626, is in development for secondary stroke prevention with additional clinical potential for stroke prevention in atrial fibrillation.”

    Latest 424B4final IPO prospectusPositivePre-revenue ·

    Develops siRNA drugs for hereditary angioedema and other diseases; $446M all-primary raise funds clinical development

  • AMGN Amgen

    Sells it 8%, $3.0B a year“Repatha was launched in 2015 and is indicated to reduce the risk of major adverse cardiovascular (CV) events (CV death, myocardial infarction, stroke, unstable angina requiring hospitalization, or coronary revascularization) in adults at increased risk for these events.”

    Latest 10-QQ3 FY2026 ·

    Repatha, UPLIZNA and IMDELLTRA demand more than offsets biosimilar erosion in Prolia and XGEVA.

    • Revenue$10.4BYoY +8.5%
    • Net income$3.9BYoY +20.1%
  • BMY Bristol-Myers Squibb

    Sells it 32%, $15.5B a year“Eliquis (apixaban) is an oral Factor Xa inhibitor indicated for the reduction in risk of stroke/systemic embolism in NVAF and for the treatment of DVT/PE and reduction in risk of recurrence following initial therapy.”

    Latest 10-QQ3 FY2026MixedImpairment / charge ·

    Eliquis drove growth as generics eroded Revlimid and Pomalyst; pipeline licensing charges weighed on earnings.

    • Revenue$13.1BYoY +6.9%
    • Net income$2.2BYoY −1.8%
  • BRVE Braveheart Bio, Inc.

    In development“Our lead product candidate, BHB-1893, is a next-generation oral small-molecule cardiac myosin inhibitor (“CMI”), that we are developing for the treatment of obstructive HCM (“oHCM”) and non-obstructive HCM (“nHCM”).”

    Latest 424B4final IPO prospectusPositiveImpairment / chargePre-revenueRelated-party dependence ·

    Develops BHB-1893, an oral cardiac myosin inhibitor for hypertrophic cardiomyopathy; $383M all-primary raise funds Phase 3 trials.

  • BSX Boston Scientific

    Sells it“Cardiovascular growth benefited from the AGENT drug-coated balloon; Farapulse pulsed-field ablation also supported year-to-date growth.”

    Latest 8-KLeadership changeExecutive pay ·

    David S. Wichmann to succeed Ludwig as lead independent director; 2027 executive incentives tie payouts to sales, adjusted EPS and shareholder returns

  • CTY CITY THERAPEUTICS, INC.

    In development“We are advancing CITY-FXI for the prevention of thromboembolic diseases based on its potential to reduce FXI activity and thereby prevent thromboembolic events while mitigating bleeding risk.”

    Latest 424B4final IPO prospectusCustomer concentration ·

    Develops RNA interference drugs led by CITY-FXI for thrombosis; raises $200M entirely through new shares.

  • EMI Encore Medical, Inc.

    Sells it“Septal occlusion devices are small, implantable devices that are positioned and delivered through a catheter inserted into a major blood vessel (typically via femoral venous access) to repair certain cardiac defects in both adults and children.”

    Latest S-1/Aamended IPO prospectusNegativeBankruptcy / going concernAccounting issueCustomer concentration ·

    Sells catheter-delivered devices to close holes in the heart; IPO triggers a $7M technology license outside its core business

  • JNJ Johnson & Johnson

    Sells it“Cardiovascular and Metabolism (e.g., thrombosis, diabetes and macular degeneration).”

    Latest 10-QQ3 FY2026MixedRestructuringImpairment / chargeLegal / investigation ·

    TREMFYA and oncology growth offset STELARA’s biosimilar erosion, but a proposed talc-settlement charge nearly wiped out earnings.

    • Revenue$25.4BYoY +5.9%
    • Net income$210.0MYoY −95.9%
  • LLY Eli Lilly and Company

    Sells it“Jardiance In collaboration with Boehringer Ingelheim, for the treatment of type 2 diabetes; to reduce the risk of cardiovascular death in adult patients with type 2 diabetes and established cardiovascular disease; to reduce the risk of cardiovascular death and hospitalizations for heart failure in adults; and to reduce the risk of sustained decline in estimated glomerular filtration rate (eGFR), end-stage kidney disease, cardiovascular death and hospitalization in adults with chronic kidney disease (CKD) at risk of progression.”

    Latest 10-QQ3 FY2026PositiveImpairment / charge ·

    Mounjaro and Zepbound volume growth outweighed lower prices, while acquired research charges constrained profit growth.

    • Revenue$24.4BYoY +38.6%
    • Net income$6.5BYoY +15.5%
  • MDT Medtronic

    Sells it“Cardiovascular growth was led by pulsed-field ablation, cardiac pacing and defibrillation; ICT also benefited from TAVR and renal denervation products.”

    Latest 8-KPositiveDeal completedLeadership changeExecutive pay ·

    MiniMed separation completed after the exchange offer was 5.4x subscribed.

  • MRK Merck & Co.

    Sells it 3%, $2.2B a year“Winrevair (sotatercept-csrk), an activin signaling inhibitor indicated for the treatment of adults with pulmonary arterial hypertension (PAH, Group 1 pulmonary hypertension) to improve exercise capacity and World Health Organization (WHO) functional class (FC), and reduce the risk of clinical worsening events including hospitalization for PAH, lung transplantation and death;”

    Latest 8-KLeadership change ·

    Douglas M. Baker Jr. succeeds Thomas H. Glocer as independent lead director Jan. 1, 2027, ahead of Glocer’s May 2027 board retirement.

  • OURA Oura Inc.

    Sells it“Continuous cardiovascular measurements are contextualized against personalized baselines.”

    Latest S-1/Aamended IPO prospectusPositiveLegal / investigationProceeds to insiders or debt ·

    Smart rings and health subscriptions; offering mainly benefits selling holders, while company proceeds largely cover equity-award taxes

  • PFE Pfizer

    Sells it“Internal medicine product portfolio including in cardiovascular metabolic diseases – select products include: Eliquis, as well as other brands that have experienced patent-based expirations or loss of regulatory exclusivity.”

    Latest 8-KCEO/CFO change ·

    Interim CFO Cecile Guegan appointed permanent CFO and EVP, effective Nov. 1.

  • RZRA Rezera Inc.

    In development“When NLRP3 becomes chronically activated, it stimulates this cascade of inflammatory mediators that drive the development and progression of cardiovascular and neuroinflammatory disease.”

    Latest S-1/Aamended IPO prospectusBankruptcy / going concernAccounting issueCEO/CFO change ·

    Develops oral anti-inflammatory drugs; IPO funds a pivotal ruvonoflast trial in peripheral artery disease, its first test in these patients.

  • SCTX Scribe Therapeutics, Inc.

    In development“Our focus is on cardiovascular and metabolic, or CVM, diseases with initial programs to address the key drivers of atherosclerotic cardiovascular disease, or ASCVD.”

    Latest 424B4final IPO prospectusMixedBankruptcy / going concernCustomer concentration ·

    Develops CRISPR medicines to lower cholesterol; $129M all-primary raise funds STX-1150 trials and pipeline development.

Feedback